.jpg?format=webp&quality=80&width=3840)
A study compared ustekinumab maintenance intervals for inflammatory bowel disease (IBD), assessing efficacy and safety. Evaluating 1448 patients across short, medium, and long-term follow-ups, both every 8 weeks (Q8W) and every 12 weeks (Q12W) showed similar efficacy in achieving clinical remission, response, and histologic improvement. However, Q12W demonstrated significantly better safety outcomes, with lower risk of adverse events. The findings suggest that while both intervals effectively manage IBD, Q12W may offer improved safety profiles during maintenance therapy.
Like
Save
Share